Table 1.

Rapid-acting, long-acting, and premixed insulin analogs.

Analog	Trade name/manufacturer	Insulin molecule modifications
Rapid-acting analogs
Lispro	Humalog/Eli Lilly	Pro(B28)/Lys(B29) switched
Aspart	Novolog/Novo Nordisk	Asp replaces Pro(B28)
Glulisine	Apidra/Sanofi-Aventis	Asp(B3) replaced by Lys; Lys(B29) replaced by Glu
Long-acting analogs
Glargine	Lantus/Sanofi-Aventis	Asp(A21) replaced by Gly; 2 Arg added to C-terminus of B-chain
Detemirt	Levemir/Novo Nordisk	Thr(B30) omitted; C14 fatty acid chain added at B29
Premixed analogs
75% neutral protamine lispro, 25% lispro	75/25 Humalog/Eli Lilly	NA
50% neutral protamine lispro, 50% lispro	50/50 Humalog/Eli Lilly	NA
70% protamine aspart, 30% aspart	70/30 Novolog/Novo Nordisk	NA

Asp, aspartic acid; Arg, arginine; Glu, glutamic acid; Lys, lysine; Pro, proline; Thr, threonine; NA, not applicable.